Market News (Page 5) - TendieTensor

Market News Page 5 of 188 • 4,690 articles

Is Amazon Stock a Buying Opportunity for 2026?

The Motley Fool • Parkev Tatevosian, Cfa

Is Amazon Stock a Buying Opportunity for 2026?

12/09/2025 04:31 AM • Amazon has underperformed the broader stock market indexes in 2025, but potential accelerating growth in AWS could drive the stock higher in 2026.

AMZN - Current underperformance in 2025, but potential for growth in AWS suggests potential future positive performance

#Amazon #AWS #stock performance #2026 investment

gRNA Market Size Worth USD 3,171.65 Million By 2034 Fueled by Rapid Expansion of Gene Editing Applications

GlobeNewswire Inc. • Precedence Research

gRNA Market Size Worth USD 3,171.65 Million By 2034 Fueled by Rapid Expansion of Gene Editing Applications

12/09/2025 03:38 AM • The global gRNA market is projected to grow from USD 708.92 million in 2025 to USD 3,171.65 million by 2034, with a CAGR of 18.16%. North America leads the market, while Asia-Pacific is expected to witness the fastest growth, driven by increasing gene editing applications and technological advancements.

PFE - Competing in Metsera acquisition but currently losing out to Novo Nordisk's offer
TMO - Identified as a key player in a market expected to grow substantially, indicating strong market positioning

#gRNA #CRISPR #gene editing #biotechnology #genome engineering

Adobe, Oracle, Broadcom Earnings Preview: Sales and AI Demand in Spotlight

Investing.com • Louis Navellier

Adobe, Oracle, Broadcom Earnings Preview: Sales and AI Demand in Spotlight

12/09/2025 02:54 AM • Three major tech companies are preparing to report earnings, with AI demand and sales growth being key focus areas. Adobe, Oracle, and Broadcom are expected to show varying levels of growth driven by cloud transformation and AI market opportunities.

NVO - Actively pursuing Metsera acquisition with increasingly competitive bids
ADBE - Expected 9% sales rise and 12% earnings growth, with a strong position in AI-driven creative market

#earnings #AI #cloud transformation #tech stocks #sales growth

NBPE Announces Transaction in Own Shares

GlobeNewswire Inc. • Nb Private Equity Partners

NBPE Announces Transaction in Own Shares

12/09/2025 02:00 AM • NB Private Equity Partners bought back 30,000 Class A Shares at prices between £15.36 and £15.60 on the London Stock Exchange, which will be cancelled, reducing outstanding shares to 43,635,579.

NBGX - Mentioned as the parent company of the investment manager, with no specific positive or negative indicators in the article

#share buyback #London Stock Exchange #Class A Shares #equity investment

Nvidia’s H200 Victory in China: Winning Permission to Sell What Beijing Won’t Buy

Investing.com • Luis Flavio Nunes

Nvidia’s H200 Victory in China: Winning Permission to Sell What Beijing Won’t Buy

12/09/2025 01:39 AM • Nvidia received export approval for H200 chips to China, but historical precedent suggests Beijing may discourage Chinese tech firms from purchasing, rendering the approval potentially meaningless.

NVDA - Despite export approval, China has consistently blocked American chip purchases to promote domestic semiconductor development, making the H200 chip sale unlikely and potentially resulting in another revenue write-off

#semiconductor #export controls #China market #AI chips #trade restrictions

Netcapital Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc. • Netcapital Inc.

Netcapital Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12/08/2025 08:31 PM • Netcapital Inc. granted a new employee 1,000,000 shares of restricted stock, with vesting contingent on achieving revenue targets between $900,000 and $1,500,000 by January 31, 2027.

REPL - Demonstrated clinical progress with RP1 therapy and potential for improving cancer treatment outcomes
NCPL - The company is making a standard equity compensation grant with performance-based vesting conditions, indicating routine business activity without significant positive or negative implications

#restricted stock #equity incentive #revenue targets #inducement award

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

GlobeNewswire Inc. • Ascentage Pharma

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

12/08/2025 07:45 PM • Ascentage Pharma presented updated clinical trial data for Olverembatinib, showing promising efficacy in treating chronic myeloid leukemia patients who failed previous treatments, with 76.7% complete cytogenetic response rate and deepening molecular responses over time.

TAK - Has signed an exclusive option agreement for global rights to Olverembatinib outside of certain Chinese territories

#Olverembatinib #CML #clinical trial #BCR-ABL1 inhibitor #hematology

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

GlobeNewswire Inc. • Ascentage Pharma Group International

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

12/08/2025 07:45 PM • Ascentage Pharma presented promising Phase III study results for Olverembatinib in treating Philadelphia chromosome-positive acute lymphoblastic leukemia, showing a 66% minimal residual disease negativity rate and favorable safety profile.

TAK - Signed an exclusive option agreement for global rights to Olverembatinib, indicating potential strategic interest

#Olverembatinib #Ph+ ALL #clinical trial #BCR-ABL inhibitor #hematology

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

GlobeNewswire Inc. • Ascentage Pharma

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

12/08/2025 07:45 PM • Ascentage Pharma presented four-year follow-up data for Olverembatinib, demonstrating improved disease control and safety in treating chronic myeloid leukemia patients resistant to existing tyrosine kinase inhibitors.

GOOGL - Mentioned as a technology partner for SecOps platform, with no significant positive or negative implications
IVBIY - Mentioned as joint commercialization partner for Olverembatinib in China with no specific performance details

#Olverembatinib #CML #tyrosine kinase inhibitor #clinical trial #leukemia

RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO

GlobeNewswire Inc. • Jerry Katzman, Md

RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO

12/08/2025 07:43 PM • RetinalGenix Technologies has hired M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026. Zwerling brings over three decades of global experience in healthcare, finance, and operations to help the company transition from R&D to early commercial operations.

RTGN - The company is expanding its leadership team with an experienced executive, preparing for commercialization, and developing breakthrough technologies for early disease detection

#retinal imaging #genetic testing #healthcare technology #medical devices #early disease detection

UPDATE - Broadway Star Morgan Dudley Joins Stargaze as Creative Advisor

GlobeNewswire Inc. • Steve Mandell

UPDATE - Broadway Star Morgan Dudley Joins Stargaze as Creative Advisor

12/08/2025 06:53 PM • Broadway performer Morgan Dudley has joined Stargaze Entertainment Group as a Creative Advisor, returning to the platform that originally helped launch her career in 2019. She will contribute to community-building and help emerging talents gain industry exposure.

BNS - Mentioned as previous workplace of Jerrold Annett, with no specific performance context
STGZ - The company is expanding its platform, bringing back a successful alumni as a Creative Advisor, and highlighting its track record of helping nearly 1,000 talents launch their careers

#talent discovery #Broadway #entertainment platform #career breakthrough

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX

12/08/2025 06:45 PM • Rosen Law Firm is notifying Telix Pharmaceuticals investors about a securities class action lawsuit alleging false statements regarding prostate cancer therapeutic candidates and supply chain quality during February 21-August 28, 2025.

TLX - The lawsuit alleges the company made materially false and misleading statements about its prostate cancer therapeutic progress and supply chain quality, suggesting potential corporate misconduct and investor harm

#securities #class action #lawsuit #investor rights #false statements

The Motley Fool • Reuben Gregg Brewer

Is Citigroup Stock a Buy Now?

12/08/2025 06:34 PM • Citigroup's stock has risen 50% over the past year, outperforming the average large U.S. bank. While the company shows strong business performance, the stock appears fully valued or slightly expensive, making it less attractive for value investors.

C - Stock has performed well with 50% rise, but current valuation metrics suggest it's fully priced and may not have significant further upside potential

#banking #stock valuation #investor sentiment #market performance

Why Wave Life Sciences Stock Vaulted 146% Higher on Monday

The Motley Fool • Eric Volkman

Why Wave Life Sciences Stock Vaulted 146% Higher on Monday

12/08/2025 06:30 PM • Wave Life Sciences saw a massive stock surge after reporting promising phase 1 clinical trial results for its investigational weight loss drug WVE-007, which demonstrated significant body fat reduction and potential competitive advantages over existing GLP-1 drugs.

WVE - Reported successful clinical trial results with 4.5% total body fat reduction, exceeded expectations, and showed potential competitive advantages over existing weight loss drugs

#weight loss #biotech #clinical trial #drug development #obesity

AI UltraProd Announces U.S. Market Entry with Strategic Focus on High-Growth ADU Sector

GlobeNewswire Inc. • Na

AI UltraProd Announces U.S. Market Entry with Strategic Focus on High-Growth ADU Sector

12/08/2025 06:00 PM • AI UltraProd, a subsidiary of SecureTech Innovations, is entering the U.S. market by focusing on the Accessory Dwelling Unit (ADU) sector, leveraging AI-driven robotic 3D printing technology to revolutionize construction with faster, more sustainable, and affordable residential solutions.

GSpC - Referenced in market capitalization comparison without substantive analysis
SCTH - Supporting subsidiary's market entry, showing strategic growth in AI and industrial technologies, with potential for future expansion across multiple sectors

#AI #3D printing #robotic construction #ADU #housing market #technology innovation

JHX IMPORTANT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages James Hardie Industries plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – JHX

GlobeNewswire Inc. • Rosen Law Firm

JHX IMPORTANT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages James Hardie Industries plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – JHX

12/08/2025 05:58 PM • Rosen Law Firm alerts James Hardie Industries investors about a potential securities class action lawsuit alleging the company misled investors about its North America Fiber Cement segment's performance between May and August 2025.

GSpD - Referenced in market capitalization comparison without substantive analysis
JHX - The lawsuit alleges the company falsely claimed demand was strong and stock levels were 'normal' despite knowing distributors were destocking inventory, suggesting potential intentional misrepresentation of financial performance

#securities #class action #investor rights #misleading statements

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DexCom and CarMax and Encourages Investors to Contact the Firm

GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DexCom and CarMax and Encourages Investors to Contact the Firm

12/08/2025 05:53 PM • Law firm Bragar Eagel & Squire announced class action lawsuits against DexCom and CarMax, alleging false statements and misleading investors about business operations and prospects.

DXCM - Lawsuit alleges unauthorized device design changes, reduced reliability of glucose monitoring devices, potential health risks, and misleading statements about product enhancements

#class action #lawsuit #securities #investor rights

TEN Ltd. Receives Best Deal of the Year Award at the 2025 Lloyds List Greek Shipping Awards

GlobeNewswire Inc. • Ten Ltd.

TEN Ltd. Receives Best Deal of the Year Award at the 2025 Lloyds List Greek Shipping Awards

12/08/2025 05:00 PM • TEN Ltd. was recognized with the 'Best Deal' Award for its significant expansion into the shuttle tanker market, growing its fleet to 16 vessels with a $3.0 billion revenue backlog and becoming one of the world's largest shuttle tanker owners.

AXP - Mentioned as a comparative market capitalization reference point
TEN - Company received an industry award, expanded its fleet, demonstrated strong revenue potential, and highlighted significant growth in shuttle tanker operations

#shuttle tanker #maritime #fleet expansion #energy transportation

Netcapital Inc. Announces Appointment of Rich Wheeless as CEO

GlobeNewswire Inc. • Rich Wheeless

Netcapital Inc. Announces Appointment of Rich Wheeless as CEO

12/08/2025 05:00 PM • Netcapital Inc. appointed Rich Wheeless as new CEO, signaling strategic expansion into crypto and blockchain investments, with plans to help small businesses integrate new financial technologies.

NCPL - New leadership with extensive financial experience, strategic pivot into emerging technologies, and clear growth strategy indicates positive organizational momentum

#crypto #blockchain #fintech #capital markets #digital securities

Nayax Announces Preliminary Results of Notes and Warrants Offering in Israel to Qualified Investors

GlobeNewswire Inc. • Nayax Ltd.

Nayax Announces Preliminary Results of Notes and Warrants Offering in Israel to Qualified Investors

12/08/2025 04:58 PM • Nayax Ltd. completed a tender offering of notes and warrants to qualified investors in Israel, raising approximately NIS 565.5 million. The offering includes Series A Notes with a 5.9% fixed annual interest rate, maturing in 2030, and warrants exercisable into company shares.

GS - Referenced in market capitalization comparison without substantive analysis
NYAX - The company successfully raised significant capital (approximately $175 million) through a strategic notes and warrants offering, indicating strong investor confidence and potential for future growth and acquisitions

#notes #warrants #tender #financing #Israel #capital raise

Aeroméxico November 2025 Traffic Results

GlobeNewswire Inc. • Grupo Aeroméxico

Aeroméxico November 2025 Traffic Results

12/08/2025 04:31 PM • Aeroméxico reported a 2.0% year-over-year decrease in passenger transportation in November 2025, with total passengers at 1.995 million. Despite reduced capacity, the airline maintained a high load factor of 87.5% and remains recognized as the world's most punctual carrier in 2025.

GSpA - Referenced in market capitalization comparison without substantive analysis
AERO - While passenger numbers and capacity decreased, the company showed operational resilience with high load factors and punctuality, suggesting stable performance

#aviation #passenger transportation #load factor #operational results

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

GlobeNewswire Inc. • Arcutis Biotherapeutics, Inc.

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

12/08/2025 04:00 PM • Arcutis Biotherapeutics appointed Amit Munshi to its Board of Directors and announced the retirement of founder Bhaskar Chaudhuri, marking a leadership transition for the biopharmaceutical company.

ARQT - Company is expanding leadership, welcoming an experienced executive, and continuing to grow its commercial presence and pipeline

#board appointment #leadership transition #dermatology #ZORYVE

Ascent Solar Technologies Announces Closing of Up to $5.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire Inc. • Ascent Solar Technologies

Ascent Solar Technologies Announces Closing of Up to $5.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

12/08/2025 04:00 PM • Ascent Solar Technologies closed a private placement offering of 1,025,643 shares and warrants, raising approximately $2 million upfront with potential additional proceeds of $3.5 million from warrant exercises.

ASTI - The company is raising capital through a private placement, which suggests a need for working capital but is a standard financing method for growth and operational needs

#private placement #warrants #financing #solar technology

Camposol S.A. Commences Tender Offer for Any and All of Its 6.000% Notes Due 2027

GlobeNewswire Inc. • Camposol S.A.

Camposol S.A. Commences Tender Offer for Any and All of Its 6.000% Notes Due 2027

12/08/2025 03:48 PM • Camposol S.A. announced a cash tender offer for its outstanding 6.000% Notes due 2027, with a total outstanding principal amount of U.S.$311,768,000. The tender offer will expire on December 16, 2025, with holders eligible to receive U.S.$1,000 per U.S.$1,000 principal amount of notes tendered.

AMJB - Serving as dealer manager for the tender offer, which is a standard financial service role

#tender offer #notes #debt #financial transaction

ROSEN, THE FIRST FILING FIRM, Encourages CarMax, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – KMX

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, THE FIRST FILING FIRM, Encourages CarMax, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – KMX

12/08/2025 03:45 PM • Rosen Law Firm alerts CarMax investors about a securities class action lawsuit regarding potentially misleading statements about the company's growth prospects during June 20-November 5, 2025.

KMX - The lawsuit alleges that CarMax made materially false and misleading statements about its growth prospects, suggesting the company potentially misrepresented its financial performance and market position

#securities #class action #lawsuit #investor rights #stock